Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma?

Roland Eid; Elie Nemr; Fady Gh Haddad; Hampig Raphael Kourie; Joseph Kattan

doi:10.2217/fon-2017-0559

Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma?

Future Oncol. 2018 Apr;14(8):677-680. doi: 10.2217/fon-2017-0559. Epub 2018 Mar 9.

Authors

Roland Eid¹, Elie Nemr², Fady Gh Haddad¹, Hampig Raphael Kourie¹, Joseph Kattan¹

Affiliations

¹ Faculty of Medicine, Hematology-Oncology Department, Saint-Joseph University, Beirut, Lebanon.
² Faculty of Medicine, Urology Department, Saint-Joseph University, Beirut, Lebanon.

PMID: 29521122
DOI: 10.2217/fon-2017-0559

No abstract available

Keywords: PD-L1; checkpoint inhibitors; metastatic; ongoing trials; penile carcinoma; preliminary results; rare cancers; rationale; standard therapy; treatment.

Publication types

Editorial

MeSH terms

B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / genetics*
Carcinoma / drug therapy*
Carcinoma / epidemiology
Carcinoma / genetics
Carcinoma / pathology
Humans
Male
Neoplasm Metastasis
Penile Neoplasms / drug therapy*
Penile Neoplasms / epidemiology
Penile Neoplasms / genetics
Penile Neoplasms / pathology
Risk Factors

Substances

B7-H1 Antigen
CD274 protein, human